methicillin-resistant S. aureus (MRSA) infections in hospitalized patients
March 2011
New guidelines will clarify the treatment of methicillin-resistant S. aureus (MRSA) infections in hospitalized patients.
Choose treatments based on the infection site, patient's age, antibiotic sensitivities, patient tolerance, cost, etc.
Keep in mind the newer drugs (daptomycin, linezolid, telavancin) cost about $200 per day...ten times more than the older ones (clindamycin, TMP/SMX, vancomycin).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote